SEC Company Response from Enlivex Ltd. (ENLV) (CIK 0001596812) (ENLV) — Jul 5, 2019

Enlivex Ltd. (ENLV) (CIK 0001596812)
Date: July 5, 2019 · CIK: 0001596812 · Accession: 0001213900-19-012138

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-232413

Date

June 28, 2019

Author

Enlivex

Form

CORRESP

Company

Enlivex Ltd. (ENLV) (CIK 0001596812)

Letter

Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance Attention: Ada D. Sarmento Re: Enlivex Therapeutics Ltd. Registration Statement filed on Form F-3 Filed on June 28, 2019 File No. 333-232413

Dear Ms. Sarmento:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Enlivex Therapeutics Ltd. (the “Company”) hereby requests acceleration of the effective date of the above-referenced registration statement so that it will become effective at 5:00 p.m., Eastern Daylight Time, on Tuesday, July 9, 2019, or as soon as practicable thereafter.

Should you have any questions or comments regarding this matter, please contact the undersigned at +972.2.6708072 or the Company’s legal counsel, Robert L. Grossman, Esq. at (305) 579-0756 or Drew Altman, Esq. at (305) 579-0589, each of Greenberg Traurig, P.A.

The Company hereby authorizes Drew M. Altman of Greenberg Traurig, P.A. to orally modify or withdraw this request for acceleration.

Sincerely,
Enlivex
Therapeutics, Ltd.

Show Raw Text

CORRESP
1
filename1.htm

Enlivex
Therapeutics Ltd.

14
Einstein Street

Nes
Ziona

Israel
7403618

July
5, 2019

Via
EDGAR

United
States Securities and Exchange Commission

Division
of Corporation Finance

100
F Street, N.E.

Washington,
D.C. 20549

Attention: Ada
                                         D. Sarmento

Re: Enlivex
                                         Therapeutics Ltd.

Registration
Statement filed on Form F-3

Filed
on June 28, 2019

File
No. 333-232413

Dear
Ms. Sarmento:

Pursuant
to Rule 461 under the Securities Act of 1933, as amended, Enlivex Therapeutics Ltd. (the “Company”) hereby requests
acceleration of the effective date of the above-referenced registration statement so that it will become effective at 5:00 p.m.,
Eastern Daylight Time, on Tuesday, July 9, 2019, or as soon as practicable thereafter.

Should
you have any questions or comments regarding this matter, please contact the undersigned at +972.2.6708072 or the Company’s
legal counsel, Robert L. Grossman, Esq. at (305) 579-0756 or Drew Altman, Esq. at (305) 579-0589, each of Greenberg Traurig, P.A.

The
Company hereby authorizes Drew M. Altman of Greenberg Traurig, P.A. to orally modify or withdraw this request for acceleration.

    Sincerely,

    Enlivex
    Therapeutics, Ltd.

    By:
    /s/
    Shai Novik

    Name:
    Shai
    Novik

    Title:
    Executive
    Chairman

cc: Robert
                                         L. Grossman, Esq.

Drew
M. Altman, Esq.

Greenberg
Traurig, P.A.

SecProbe.io